Search Results for "Her2 Infusion"
Original Source: Her2 Chimeric Antigen Receptor Expressing T Cells in Advanced Osteosarcoma
To determine the safety of one intravenous injection of autologous HER2-specific T cells according to the following dosing schedules: Dose level 1: 1 x 10^7 cells/m2 Dose level 2: 1 x 10^8 cells/m2 Dose level 3: 1 x 10^9 cells/m2 This Phase I dose-escalation trial is designed to evaluate the safety of escalating doses of autologous HER2-specific T cells. This study will utilize the modified continual reassessment method with 2 patients per dose level. All patien...
Matching Channels
Targeted treatment of Her2-positive breast cancer with the anti-Her2 antibody trastuzumab has become an example of successful personalized medicine. The commercial success of Herceptin (trastuzumab)...
The humanized anti-Her2 monoclonal antibody Herceptin (trastuzumab) has become the mainstay in the treatment of Her2-positive breast cancer. Combining trastuzumab with the potent cytotoxic DM1 via a s...
Human Epidermal Growth Factor receptor EGF R
The human epidermal growth factor receptor (HER) family members include EGFR (erbB1), HER2/neu (erbB2), HER3 (erbB3), and HER4 (erbB4) that are structurally related, and all except HER3 contain intr...
Matching News
StnDrd Infusion Inc.’s StnDrd Infusion Therapy System streamlines general-purpose infusion pumps by combining within one device the ability to effectively and safely infuse all three classifications...
FDA approves new treatment for HER2-positive late-stage breast Cancer
The United States Food and Drug Administration (FDA), under its priority review program, recently approved PerjetaTM (pertuzumab), a HER2/neu receptor antagonist indicated in combination with Herc...
Breast Cancer Stem Cells Express HER2, Even In 'Negative' Tumors, Study Finds
New research from the University of Michigan Comprehensive Cancer Center finds that the protein HER2 plays a role even in breast cancers that would traditionally be categorized as HER2-negative - and...
Notion of using herceptin only for HER2-positive breast cancer challenged
New research finds that the protein HER2 plays a role even in breast cancers that would traditionally be categorized as HER2-negative – and that the drug Herceptin, which targets HER2, may have an e...
Subcutaneous administration of Herceptin preferred by HER2-positive breast cancer patients over IV
Results from the PrefHer (Patient Preference for Subcutaneous (SC) versus Intravenous (IV) Herceptin) trial show that 92% of early HER2-positive breast cancer patients favoured quicker SC administrati...
U-M study challenges notion of using Herceptin only for HER2-positive breast cancer
ANN ARBOR, Mich. — New research from the University of Michigan Comprehensive Cancer Center finds that the protein HER2 plays a role even in breast cancers that would traditionally be categorized as...
New results from a retrospective study conducted in Europe suggest that anti-HER2 treatments, like the widely used breast cancer agent trastuzumab (Herceptin), have anti-cancer effects in a small subs...
HER2-positive breast cancer patients prefer faster subcutaneous administration of Herceptin to IV
Results from the PrefHer (Patient Preference for Subcutaneous (SC) versus Intravenous (IV) Herceptin) trial show that 92% of early HER2-positive breast cancer patients favored quicker SC administratio...
Matching PubMed Articles
HER2/neu is an oncogene amplified and over-expressed in 20-30% of breast adenocarcinomas. Treatment with the humanized monoclonal antibody trastuzumab has shown efficacy in combination with cytotoxic...
Intratumoral heterogeneity of HER2 status in breast carcinoma.
Intratumoral heterogeneity of HER2 protein expression and HER2 gene amplification can negatively affect determination of HER2 status in a subset of invasive breast carcinomas. The frequency and clinic...
The overexpression of HER2/neu receptor plays a key role in tumorigenesis and tumor progression. Small molecules targeting HER2/neu have therapeutic value in cancers that overexpress HER2. In this pre...
Sensitivity of CA 15-3, CEA and serum HER2 in the early detection of recurrence of breast cancer.
Abstract Background: The aim of this project was to investigate the sensitivity of CA 15-3, CEA and HER2 in the early diagnosis of metastatic breast cancer. Methods: Serial serum values of CA 15-3, CE...
In this paper, we present a mathematical model predicting the fraction of proliferating cells in G1, S, and G2/M phases of the cell cycle as a function of EGFR and HER2. We show that it is possible to...
